Latest receivables for MNLO: $11M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Menlo Therapeutics (MNLO) currently reports a receivables of $11M as of September 2020. In the prior-year period, the figure was $0. Use the charts on this page to explore Menlo Therapeutics's receivables history and peer comparisons.
Menlo Therapeutics's receivables changed from $0 to $11M (period ending September 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Menlo Therapeutics reported $11M in receivables as of September 2020. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Menlo Therapeutics, and consider following MNLO for alerts when major investors trade the stock.
Menlo Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MNLO with unrelated industries.